Drug Profile
BKC 1501A
Alternative Names: BKC-1501ALatest Information Update: 19 Oct 2021
Price :
$50
*
At a glance
- Originator Bukwang Pharmaceutical
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 01 Oct 2021 Preclinical trials in Autoimmune disorders in South Korea (unspecified route) (Bukwang Pharmaceutical pipeline, October 2021).
- 04 Oct 2017 Early research in Autoimmune disorders in South Korea before October 2017 (Bukwang Pharmaceuticals pipeline, October 2017)